DJE Kapital AG Sells 78,401 Shares of Gilead Sciences, Inc. $GILD

DJE Kapital AG reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,522 shares of the biopharmaceutical company’s stock after selling 78,401 shares during the period. DJE Kapital AG’s holdings in Gilead Sciences were worth $22,647,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of GILD. Brighton Jones LLC grew its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter valued at approximately $215,000. Sivia Capital Partners LLC raised its stake in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the last quarter. Ieq Capital LLC raised its stake in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC boosted its holdings in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer owned 607,133 shares of the company’s stock, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 77,000 shares of company stock worth $9,978,740. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $133.21 on Tuesday. The business’s fifty day simple moving average is $129.72 and its two-hundred day simple moving average is $135.37. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12 month low of $107.75 and a 12 month high of $157.29. The company has a market cap of $165.39 billion, a price-to-earnings ratio of 18.15 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the company earned $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. The Goldman Sachs Group increased their target price on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research report on Wednesday, May 20th. Finally, Rothschild & Co Redburn reduced their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Twenty-six research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.